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ABSTRACT
Background Reducing geographical inequalities in
cancer survival in England was a key aim of the
CalmaneHine Report (1995) and the NHS Cancer Plan
(2000). This study assesses whether geographical
inequalities changed following these policy developments
by analysing the trend in 1-year relative survival in the 28
cancer networks of England.
Methods Population-based age-standardised relative
survival at 1 year is estimated for 1.4 million patients
diagnosed with cancer of the oesophagus, stomach,
colon, lung, breast (women) or cervix in England during
1991e2006 and followed up to 2007. Regional and
deprivation-speciﬁc life tables are built to adjust survival
estimates for differences in background mortality.
Analysis is divided into three calendar periods: 1991e5,
1996e2000 and 2001e6. Funnel plots are used to
assess geographical variation in survival over time.
Results One-year relative survival improved for all
cancers except cervical cancer. There was a wide
geographical variation in survival with generally lower
estimates in northern England. This northesouth divide
became less marked over time, although the overall
number of cancer networks that were lower outliers
compared with the England value remained stable.
Breast cancer was the only cancer for which there was
a marked reduction in geographical inequality in survival
over time.
Conclusion Policy changes over the past two decades
coincided with improved relative survival, without an
increase in geographical variation. The northesouth
divide in relative survival became less pronounced over
time but geographical inequalities persist. The reduction
in geographical inequality in breast cancer survival may
be followed by a similar trend for other cancers, provided
government recommendations are implemented
similarly.
Reducing regional inequalities in cancer survival in
England was identiﬁed as a public health priority
in two key policy documents relating to cancer
services in England: the CalmaneHine Report of
1995 and the NHS National Cancer Plan of 2000.
1 2
Cancer networks were founded in 2001, following
these policy developments, to improve uniformity
in the standard of cancer management and to
ensure equitable distribution of cancer facilities and
resources.
2
In this paper we present estimates of 1-year age-
standardised relative survival among adult patients
(aged 15e99 years) diagnosed with a cancer of the
oesophagus, stomach, colon, lung, breast (women)
or cervix in the 28 cancer networks (as geographi-
cally deﬁned in 2009) in England during 1991e2006
and followed up to 31 December 2007. The
temporal trend in geographical differences in
survival is analysed in three calendar periods,
selected to coincide with the above-mentioned
developments in cancer policy: 1991e5 (pre-
Calman-Hine report); 1996e2000 (post-Calm-
aneHine report); 2001e6 (post-NHS National
Cancer Plan). These periods coincide with those
used in previous published research.
3
Given their role in cancer management, cancer
networks are a logical unit for the analysis of
regional diversity in cancer survival in England.
4
Also, since the population of each cancer network is
between 0.6 and 3.0 million, they are more suitable
units of analysis of survival from individual cancers
than smaller NHS geographies such as primary care
organisations.
45
METHODS
Data
National cancer registration data for England were
obtained from the Ofﬁce for National Statistics
(ONS). The National Cancer Registry at ONS
collates cancer registrations submitted by regional
cancer registries in England. The National Health
Service Information Centre (NHS-IC) updates
these records with information about death or
emigration and returns this to ONS. The data were
extracted from the database at ONS in October
2008. Ethical approval to conduct the study was
obtained from the ONS Medical Research Service
(MR1101, 20 November 2007) and from the stat-
utory patient information advisory group (PIAG;
now the Ethics and Conﬁdentiality Committee of
the National Information Governance Board) under
Section 61 of the Health and Social Care Act 2001
(PIAG 1-05(c)/2007, 31 July 2007).
All adult patients (15e99 years) who were diag-
nosed during 1991e2006 with an invasive primary
malignancy of the oesophagus, stomach, colon,
lung, breast (women) or cervix were eligible for
inclusion in the study. They were followed up to
ascertain their vital status to 31 December 2007.
Patients were excluded if the behaviour of the
tumour was benign, in situ, or uncertain if benign
or malignant. Patients were further excluded if their
cancer was registered from a death certiﬁcate only
(DCO registration) or if they died on the same day
as diagnosis (zero survival). Zero survival cases
were excluded because before 1995 it is not possible
to distinguish between DCO registrations and zero
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Cancersurvival cases. Patients were also excluded if their record lacked
relevant geographical data. A detailed description of data
cleaning and exclusions has been published.
3 67The number of
patients included was approximately 90% of eligible records
(table 1).
There were originally 34 cancer networks in England when
they were founded in 2001.
4 Following various mergers, there are
now 28 (ﬁgure 1). We applied the current boundaries retro-
spectively to 1991, to enable consistent comparison over time.
The number of patients included for analysis in each cancer
network is shown in table 2.
Relative survival
We estimated relative survival 1 year after diagnosis for each
cancer network by cancer, sex and calendar period. Relative
survival is the ratio of the observed probability of survival and
the probability of survival that would have been expected if the
patients had experienced the normal background mortality in
the area where they live.
8e10
Relative survival is therefore a method of factoring out
background mortality and estimating survival from cancer
without requiring information on cause of death. Background
mortality was obtained from population life tables, generated
from death registration data provided by ONS. Complete (single
year of age) life tables for ages 0e99 years were built for men
and women for three index years (1991, 2001 and 2005), using
deaths for three years centred on those index years and the
midyear population.
11 Life tables for the intervening years were
created using linear interpolation. The life table for 2005 was
used for 2006 and 2007.
In England, background mortality by sex and age varies by
geographical region and socioeconomic status,
12 so life tables
were created for each government ofﬁce region and deprivation
category. Patients were assigned a deprivation score based on the
income domain of the indices of multiple deprivation (2004) of
the lower super output area of residence at the time of diag-
nosis.
13 The deprivation score was categorised according to the
quintiles of indices of multiple deprivation in the 32483 lower
super output area.
Relative survival is adjusted for background mortality by age,
butitwillvarybetweenregionsifthereareunderlying differences
in the age structure of cancer patient populations. To control
for these differences in age structure, we produced age-stand-
ardised survival using the direct method, wherein age-speciﬁc
survival is weighted by a standard population age distribution.
6
To create age-standardised estimates it is ﬁrst necessary to
estimate age-speciﬁc survival. This can be difﬁcult because of the
small number of events in some age groups when disaggregating
by cancer, cancer network, sex and calendar period.
Analytical strategy
To overcome the problem of too few events, we estimated age-
speciﬁc excess mortality (and relative survival) using a two-step
approach. Excess mortality is the observed mortality among
cancer patients minus the expected mortality in the general
population.
In the ﬁrst step, estimates were obtained using the
cohort approach, with the publicly available Stata program
strel, which uses the maximum-likelihood approach.
10 14 We
Table 1 Number of patients eligible for analysis and number excluded, for adults (15e99 years)
diagnosed with one of six cancers in England during 1991e2006
Malignancy ICD-10 code* Eligible for analysis
Exclusions
Patients included Zero
DCOy Survivalz Otherx Number (%)
Oesophagus C15 93279 4960 1702 626 85991 (92.2)
Stomach C16 127376 9377 3334 948 113757 (89.3)
Colon C18 284858 16732 6622 4761 256743 (90.1)
Lung C33, C34 511491 45725 18574 4979 442213 (86.5)
Breast (women) C50 536526 15674 4650 18773 497429 (92.7)
Cervix C53 42764 965 316 624 40859 (95.5)
*International Classiﬁcation of Diseases, tenth revision.
yRegistration from a death certiﬁcate only (DCO).
zDate of diagnosis equal to date of death but not ﬂagged as a DCO registration.
xAged 100 years or over at diagnosis, sex or vital status unknown, sex-site error, invalid dates, duplicate registration, synchronous
tumours, previous cancer of the same organ or tissue since 1971, or missing geographical data.
Figure 1 Cancer Network Boundaries, 2009.
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Cancerexcluded all unstable estimates, deﬁned a priori as follows: age,
sex, cancer network and period-speciﬁc estimates from strel
were discarded if there were no deaths in either the ﬁrst or the
second half year after diagnosis. The proportion of 1-year
excess mortality estimates by cancer, sex, age, period and
cancer network that were discarded because of non-conver-
gence or instability varied from 0% for breast and lung cancer
to 7% for cancer of the oesophagus.
In the second step, the retained excess mortality estimates
were modelled using a generalised linear model, assuming
a Poisson error distribution, which enabled us to produce more
reliable estimates of relative survival for all combinations of
cancer, sex, age group and calendar period. Calendar period,
follow-up time and ﬁve age groups (15e44, 45e54, 55e64,
65e74 and 75e99 years) were included in the model as main
effects. Interactions were added between period and age, period
and follow-up time, and follow-up time and age in order to deal
with the non-proportionality of excess hazards over time.
Backward stepwise selection was used to choose the interaction
terms, while the main effects were locked into the model.
The direct method of age standardisation was then applied
using the age-speciﬁc results for each cancer, sex, period, cancer
networkcombinationobtainedfromthegeneralisedlinear model.
The standard age weights were derived from the age distribution
of cancer patients diagnosed in England and Wales in 1996e9.
Funnel plots
Funnel plots are a means of presenting comparative data that
avoids spurious ranking of estimates for particular population
units. They permit visualisation of how much a speciﬁc value
differs from the England-wide value, given the precision of
the estimate.
3 15e17 Age-standardised 1-year relative survival
estimates were plotted for each cancer network against the
precision ofthe estimates,calculated astheinverse squareoftheir
standard errors (ﬁgure 2). The England-wide value, or ‘target’,i s
plotted as a solid horizontal line through the middle of the plots,
together with its 95.0% and 99.8% control limits (dashed lines).
The control limits around the target estimate for England were
calculated as a function of the precision range of the cancer
network-speciﬁc estimates. Cancer network-speciﬁc estimates
(numbered in the plots) falling outside the control limits repre-
sent those cancer networks showing wider disparity from the
England-wide value than could be expected due to chance alone.
RESULTS
Geographical diversity in 1-year relative survival varied by cancer
(table 3). For women diagnosed in 2001e6, the range in relative
survival across cancer networks varied from 15.9% (oesophageal
cancer), to 3.4% (breast cancer). For men, the range varied from
14.3% (oesophagus) to 7.5% (lung). Both the range and inter-
quartile range reduced over time in women for all cancers except
oesophageal cancer, for which the interquartile range increased
from 3.2% in 1991e5 to 5.5% in 2001e6. Among men, the range
widened in both oesophageal and stomach cancer and narrowed
for cancers of the lung and colon.
One-year relative survival for each cancer network is shown in
funnel plots (ﬁgure 2), comparing the ﬁrst and ﬁnal periods
(1991e5 and 2001e6, respectively).
In England, 1-year survival improved by up to 10 percentage
points for all cancers analysed here over the period 1991e2006,
with the exception of cervical cancer. In general, the dispersion
of relative survival estimates was wide and a large proportion of
cancer networks were outliers in relation to the England value.
Trends in survival and the outlying cancer networks were similar
Table 2 Number of adult patients (15e99 years) diagnosed in England during 1991e2006 and included for analysis, by cancer and cancer network
Oesophagus Stomach Colon Lung Breast Cervix
England 85991 113757 256743 442213 497429 40859
N01 Lancashire and South Cumbria 3125 4152 8466 15584 15368 1525
N02 Greater Manchester and Cheshire 5926 8451 15945 33109 29537 3073
N03 Merseyside and Cheshire 4143 5681 11024 23572 20032 2074
N06 Yorkshire 4195 6889 13097 27277 24794 2698
N07 Humber and Yorkshire Coast 2102 2876 5791 11540 10711 1284
N08 North Trent 3271 5559 9257 19771 17689 1552
N11 Pan Birmingham 3201 5123 9406 16688 18002 1770
N12 Arden 1740 2204 5160 7851 9930 865
N20 Mount Vemon 1590 2027 5225 8458 11846 754
N21 West London 1930 2357 5853 10766 13634 1056
N22 North London 1721 2398 5237 9967 12050 865
N23 North East London 1759 2991 5211 11701 11213 1025
N24 South East London 1901 2693 5335 12110 12473 1112
N25 South West London 2122 2401 7084 10635 14648 998
N26 Peninsula 3651 3747 10634 13579 18856 1344
N27 Dorset 1541 1778 6016 6486 9689 576
N28 Avon, Somerset and Wiltshire 3426 3726 10530 13370 19735 1627
N29 Three Counties 1855 1959 6179 7127 11426 678
N30 Thames Valley 3474 3704 10885 16031 23384 1528
N31 Central South Coast 3535 4105 11847 14896 21589 1481
N32 Surrey, West Sussex and Hampshire 1774 1810 5566 7875 12032 689
N33 Sussex 2374 2210 6816 9405 13286 750
N34 Kent and Medway 2734 2678 7042 12568 16202 1152
N35 Greater Midlands 3637 5344 10742 16809 19769 1773
N36 North of England 5556 9544 17623 40194 29984 2964
N37 Anglia 4356 5907 15342 21421 23381 1773
N38 Essex 2141 2557 6251 10136 13863 735
N39 East Midlands 7211 8886 19179 33287 37486 3138
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Cancerin men and women. For breast cancer, dispersion clearly reduced
over time. There were also fewer lower outliers in 2001e6 for
lung and stomach cancer in women.
To establish which cancer networks had consistently lower
relative survival than the England-wide value, we summed the
number of times each cancer network fell below the lower 99.8%
control limit on the funnel plots across the various cancers (four
in men and six in women) and the three calendar periods of
diagnosis. These sets of estimates were used to measure the
extent of geographical variability over time.
The number of relative survival estimates below the lower
99.8% control limit of the England-wide value across all three
calendar periods is shown in ﬁgure 3. An overall ﬁgure of 12 for
men or 18 for women would indicate that relative survival was
below the England lower control limit for every cancer exam-
ined, in all three periods. Cancer networks with consistently
lower survival than the England-wide value are illustrated with
darker shading. Figure 3 provides strong evidence of geographical
clustering of poor survival from the six cancers in England. For
men, poorer survival was clustered in the north, whereas cancer
networks in the south and west had survival consistent with the
England estimate. For women, the northesouth pattern was
similar, although less marked, with a larger number of outlying
estimates in the south west than found for men.
Figure 4 shows the number of survival estimates below the
99.8% control limit within each calendar period (results shown
Figure 2 Funnel plots of 1-year
relative survival in the cancer networks
of England: by cancer, sex and period.
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Cancerfor 1991e5 and 2001e6). Atotal of four in men and six in women
would indicate that the cancer network was an outlier for all
cancers examined. Although the number of cancer networks that
are lower outliers has remained relatively stable over time, the
northesouth divide was less pronounced for patients diagnosed in
2001e6 than for patients diagnosed in 1991e5.
Overall, the proportion of cancer and cancer network combi-
nations that were lower outliers compared with the England
value was relatively stable across the three calendar periods for
women, with the proportion at 24%, 26% and 24% in each of the
three periods. By contrast, for men, 21% and 22% of cancer
network-speciﬁc survival estimates were below the lower control
limit in 1991e5 and 1996e2000, respectively, but this ﬁgure rose
to 28% in the period 2001e6. The percentage of cancer network-
speciﬁc survival estimates that were outliers above the upper
control limit decreased over time. The percentage fell from 40%
to 27% for men and from 40% to 29% for women between the
ﬁrst and last calendar periods of diagnosis. Much of the reduction
occurred in the second period (1995e2000).
To consider the potential effect of variable data quality on
differences in survival by cancer network, the proportion of DCO
registrations was compared between cancer networks (by sex,
Figure 2 Continued.
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Cancercalendar period and cancer) and the correlation with relative
survival was ascertained (table 4). The variation in the proportion
of all exclusions combined depends almost solely on the propor-
tion of DCO registrations, other exclusion categories being rare or,
for multiple tumours for a given cancer site, very stable between
cancer networks. DCO registrations in conjunction with zero
survival represent 80.7% of the exclusions in this study (table 1).
Table 4 shows that the greatest variability in the proportion of
DCO registrations occurred in 1991e5, and this proportion
declined over time. There was indeed some correlation between
the proportion of DCO registrations and relative survival in this
earliest period, but no evidence of continuing correlation after
1995 (except for oesophageal cancer, for which there was some
correlation in 1996e2000).
DISCUSSION
In England, 1-year relative survival improved dramatically for all
cancers analysed, with the exception of cervical cancer, between
1991 and 2006. The lack of improvement in cervical cancer
survival has been found in previous studies and may be attrib-
utable to stage migration following the introduction of effective
screening.
18 19 Since 1998, cervical screening has reached at least
85% of eligible women in England. Near-universal screening
means that many more cancers are detected at an in situ stage,
and are removed before they become invasive. This has led to
a dramatic decline in the incidence of invasive cancers.
20e22
There is mounting evidence from other countries with near-
universal screening programmes that the invasive cancers that
are now identiﬁed tend to occur in women who have not
attended screening, or to be particularly aggressive cancers with
poor prognosis.
22e26 Given the improvement in multidisci-
plinary team working and chemotherapeutic advances for
cervical cancer since the 1990s it is more likely that screening
rather than treatment explains the plateau in survival for this
cancer.
19
The results of this study show clear geographical inequality in
survival. Cancer networks that had consistently low outlying
Figure 2 Continued.
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Table 3 One-year relative survival (%) in England, and range and IQR in 1-year relative survival across cancer networks, by cancer, calendar period of
diagnosis and sex
England (%) Overall range IQR
Cancer Sex 1991e5 1996e2000 2001e6 1991e5 1996e2000 2001e6 1991e5 1996e2000 2001e6
Oesophagus Men 26.5 30.0 36.7 14.1 17.2 14.3 3.9 5.9 5.5
Women 25.6 27.2 32.1 13.3 15.1 15.9 3.2 4.5 5.5
Stomach Men 29.5 33.9 38.8 11.4 17.1 13.9 3.8 4.8 5.1
Women 29.1 32.4 35.6 18.6 12.5 13.3 8.8 4.7 4.8
Colon Men 65.2 68.7 70.7 15.3 11.2 12.1 4.6 3.5 3.6
Women 62.7 66.3 67.8 13.9 10.8 10.9 6.1 3.6 3.7
Lung Men 21.3 24.0 26.4 9.4 7.4 7.5 4.6 2.6 2.4
Women 21.6 25.2 28.9 11.3 10.4 11.1 4.5 3.6 3.0
Breast Women 91.5 93.5 94.9 5.3 3.8 3.4 2.9 1.2 0.8
Cervix Women 82.8 82.7 82.4 10.5 9.3 8.4 2.4 3.3 3.2
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Cancersurvival estimates compared with the England estimates were
clustered across northern England and the East Midlands, while
results for southern and western cancer networks were more
consistently comparable with, or above, the England estimates.
This broadly conﬁrms the ﬁndings of previous studies that have
pointed to the northesouth divide in cancer survival in
England.
5 62 72 8
The largest increase in the proportion of cancer networks that
were low outliers occurred in the period 2001e6, following the
NHS National Cancer Plan. This increase was observed in men
only. Three of the four cancers in men were poor prognosis
cancers, compared with three of the six in women, and it is
possible that this played a role in the sex difference observed
here. To explain why the proportion of low outliers increased for
men but not women, it is also worth noting that women had
a higher degree of variation at baseline for at least two cancers:
the IQR for cancers of the oesophagus and colon was consider-
ably higher in women (table 3).
The lack of a signiﬁcant reduction in geographical inequalities
in cancer survival following the NHS National Cancer Plan
echoes previous research showing there has been little or no
reduction in the deprivation gap in short-term survival by
socioeconomic status in England in this period.
29
Given the large rise in overall survival, however, it is notable
that the geographical inequalities have not widened more
signiﬁcantly, as shown by the rather stable proportion of cancer
networks that were low survival outliers over time. Further-
more, even though the number of lower outliers remained stable
over time, the distribution of these outliers has shifted, leading
to a less-pronounced northesouth divide in survival.
Although regional disparities in survival from most of these
cancers did not fall over time, breast cancer is the exception,
with a distinct convergence of the cancer network-speciﬁc
survival estimates around the England value in the later period.
The reduced variation can partly be explained by the fact that
1-year survival from breast cancer in 2001e6 is reaching the
ceiling of 100%. Even accounting for this, it is clear that varia-
tion reduced, as can be seen by the relatively small number of
outliers outside the (very narrow) control limits on the funnel
plots in the ﬁnal period. This is an important ﬁnding given that
the improving outcomes guidance (IOG) issued in the mid-1990s
was implemented earliest for this cancer. Multidisciplinary team
working was universally established for breast cancer by the
Number of outliers (tertiles)
0
1 - 3
4 - 12
Number of outliers (tertiles)
0 - 2
3 - 6
8 - 18
Men
Women
Figure 3 The number of cancers (out of four in men and six in women)
for which relative survival fell below the lower 99.8% control limit of the
England value, totalled over three calendar periods, by sex and cancer
network.
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Figure 4 The number of cancers (out of four in men and six in women)
for which relative survival fell below the lower 99.8% control limit of the
England value, by calendar period (showing 1991e5 and 2001e6), sex
and cancer network.
1050 J Epidemiol Community Health 2011;65:1044e1052. doi:10.1136/jech.2010.126656
Cancertime it was assessed by the Audit Commission in 2001. At that
time, implementation of the IOG for lung, bowel and the
gynaecological cancers was uneven across the country.
30
If this reasoning is correct, it may be hypothesised that the
reduction in geographical inequalities for breast cancer may soon
be followed by a similar convergence in regional survival for
other cancers, provided the guidance issued in the manual for
cancer services
31 (which has now replaced the IOG) is imple-
mented with the same dedication and with equivalent resources
as for breast cancer. We may even predict that regional dispar-
ities in survival from bowel cancer will similarly decline in the
near future, since the National Cancer Peer Review of 2004e7
established that multidisciplinary teams in this sector had
caught up with the breast cancer standard.
32
A further issue to consider is the impact of screening on
regional variation in survival through earlier diagnosis. Three of
the six cancers included in this analysis were the subject of
screening programmes. National programmes of cervical and
breast cancer screening were effective throughout this study
period, and two rounds of the colorectal screening pilot were
conducted in 2000 and 2003e5 in some primary care trusts
(PCT) in the Arden cancer network (N12).
Given that the proportion of eligible women attending
screening for cervical cancer has remained stable since the late
1990s at over 80% in nearly 90% of health authorities,
21 it is
unlikely that the screening programme was responsible for the
reduction in geographical inequalities in survival during
1991e2006.
Breast cancer screening expanded during the period of study in
terms of the number of eligible women reached and the deﬁni-
tion of eligible women. By 2006, coverage was over 70% of
eligible women in 90% of PCTs and screening was contributing
to the reduction of breast cancer mortality.
33 34 However, less
than one third of invasive breast cancers are screen detected.
35 It
is therefore unlikely that expansion of the screening programme
played an important role in rising regional equality in breast
cancer survival.
The colorectal screening pilot was rolled out in several PCT in
the Coventry and Warwickshire area in 2000 and 2005e7. These
PCT became part of the Arden cancer network when it was
formed in 2002.
36 Survival from cancer of the colon did improve
very slightly in Arden relative to other cancer networks between
1996e2000 and 2001e6, but so did survival for patients with
lung cancer and in women with oesophageal and cervical cancer.
It is too early to say whether the launch of the national bowel
cancer screening programme in 2007 will reduce geographical
inequalities in survival.
37
It is unlikely that variation in the quality of registration data
has contributed to the regional inequalities identiﬁed in cancer
survival, at least since the mid-1990s. Registration quality in
England is determined by cancer registries (of which there are
eight) rather than cancer networks. The annual reports of the
United Kingdom Association of Cancer Registries show that
quality is relatively homogenous between the registries today
(with the exception of bladder cancer, see below).
38 The
proportion of eligible patients excluded from analysis through
the quality control conducted for this analysis was largely driven
by the number of DCO registrations and patients with zero
survival (making up 80.7% of all exclusions). We showed in table
4 that this proportion was indeed correlated with survival in
1991e5, but not in the later calendar periods, and that regional
diversity in the proportion of DCO has decreased.
The cancer sites included in this study were those incorporated
for survival analysis in the annual compendium of clinical and
health indicators for public health monitoring in England.
39 Bladder
and prostate cancer are also included in those indicators but were
excluded here. Results for bladder cancer were excluded because
wide changes in pathological coding, and diversity between cancer
Table 4 Range of percentage of eligible patients that were DCO registrations across cancer networks (minimum and maximum presented), Spearman
rank correlation with 1-year relative survival, by cancer, calendar period of diagnosis and sex
1991e5 1996e2000 2001e6
Cancer Sex Minimum Maximum r p value Minimum Maximum r p value Minimum Maximum r p value
Oesophagus Men 1.3 26.5 0.298 0.124 0.0 12.9 0.402 0.034 0.0 7.0 0.210 0.283
Women 1.4 24.8 0.143 0.468 0.2 16.6 0.224 0.251 0.0 8.1 0.228 0.244
Stomach Men 3.3 30.4 0.568 0.002 0.0 18.5 0.226 0.247 0.0 9.4 0.066 0.740
Women 3.5 37.4 0.585 0.001 0.2 22.4 0.067 0.734 0.0 13.4  0.078 0.694
Colon Men 1.3 23.3 0.525 0.004 0.2 14.4 0.308 0.111 0.0 7.5 0.179 0.362
Women 2.9 28.4 0.545 0.003 0.2 16.3 0.438 0.020 0.0 8.7 0.246 0.207
Lung Men 4.4 35.9 0.656 <0.001 0.2 19.5 0.324 0.093 0.0 15.1 0.068 0.731
Women 3.5 36.1 0.742 <0.001 0.4 20.8 0.232 0.235 0.0 15.9 0.278 0.152
Breast Women 0.6 13.1 0.363 0.058 0.1 7.2 0.216 0.269 0.0 4.0  0.077 0.696
Cervix Women 0.6 13.2 0.152 0.439 0.0 7.0 0.041 0.836 0.0 4.2  0.037 0.853
DCO, death certiﬁcate only.
What this study adds
There has been a lessening of the north-south divide in cancer
survival but the overall level of geographic inequality has
remained stable despite policy change. Breast cancer is the
exception, showing a reduction in geographic variation in
survival. If guidance is implemented with the same consistency
for other cancers, geographic inequality in cancer survival may
similarly decline.
What is already known on this subject
There is a north-south divide in cancer survival in England, with
lower survival in the north. Policy changes under the Labour
Government, including the NHS Cancer Plan (2000), aimed to
reduce geographic inequality in survival. It is necessary to assess
whether these policy changes have reduced geographic
inequality in survival in England. This study uses the most suit-
able unit for analysis: cancer networks, which were formed to
oversee the process.
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Cancerregistries in the implementation of those changes, have led to non-
interpretable trends in survival. Age-standardised survival from
prostate cancer proved to be very difﬁcult to estimate because of
small numbers of deaths in some age groups at the cancer network
level, so results were not reported.
We acknowledge that presenting data grouped by calendar
period disguises ﬂuctuations in trends and may not accurately
portray the timing of change; however, the small sample sizes in
the analysis by cancer network precluded the estimation of
annual relative survival. Further methodological developments
areinprogresstoenableagestandardisationforsmallpopulations,
in order that survival estimates can be produced for sparse data.
5
Acknowledgements The authors would like to thank the GIS team at the West
Midlands Cancer Intelligence Unit for supplying the cancer network digital boundary
information and the staff of the English cancer registries for collecting the data on
which this analysis is based.
Funding This study was funded by the National Cancer Intelligence Network, National
Cancer Research Institute (NCRI), 18th Floor, Portland House, Bressenden Place,
London SW1E 5RS.
Competing interests None.
Ethics approval This study was conducted with the approval of the ONS Medical
Research Service (MR1101, 20 November 2007). Patient Information Advisory Group
(PIAG; now the Ethics and Conﬁdentiality Committee of the National Information
Governance Board) under Section 61 of the Health and Social Care Act 2001 (PIAG
1-05(c)/2007, 31 July 2007).
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Expert Advisory Group on Cancer. A policy framework for commissioning cancer
services. London: Department of Health, 1995.
2. Department of Health. The NHS Cancer Plan. London: Department of Health, 2000.
3. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in
England and Wales up to 2007: an assessment of the NHS cancer plan for England.
Lancet Oncol 2009;10:351e69.
4. Ellis L, Rachet B, Coleman MP. Cancer survival indicators by cancer network:
a methodological perspective. Health Stat Quart 2007;36e41. Winter.
5. Quaresma M, Walters S, Gordon E, et al. A cancer survival index for Primary Care
Trusts. ONS 2010. http://www.statistics.gov.uk/statbase/Product.asp?vlnk¼15388
(accessed 17 Dec 2010).
6. Coleman MP, Babb P, Damiecki P, et al. Cancer survival trends in England and
Wales 1971e1995: deprivation and NHS region. Studies on medical and population
subjects no. 61. London: The Stationery Ofﬁce, 1999.
7. Walters S, Rachet B, Westlake S, et al. Cancer survival, England, patients diagnosed
2001e2006 and followed up to 2007: one-year and ﬁve-year survival for 21 common
cancers, by sex and age. ONS, 2009. http://www.statistics.gov.uk/downloads/
theme_health/cancer-survival-Eng-2001-2006.pdf (accessed 17 Dec 2010).
8. Berkson J, Gage RP. Calculation of survival rates for cancer. Proc Staff Meet Mayo
Clinic 1950;25:270e86.
9. Este `ve J, Benhamou E, Raymond L. Statistical methods in cancer research, volume
IV. Descriptive epidemiology. (IARC Scientiﬁc Publications No. 128). Lyon:
International Agency for Research on Cancer, 1994.
10. Este `ve J, Benhamou E, Croasdale M, et al. Relative survival and the estimation of
net survival: elements for further discussion. Stat Med 1990;9:529e38.
11. Cancer Research UK Cancer Survival Group. Life tables for England and Wales
by sex, calendar period, region and deprivation. 2004. http://www.lshtm.ac.uk/
ncdeu/cancersurvival/tools.htm (accessed 17 Dec 2010).
12. Woods LM, Rachet B, Riga M, et al. Geographical variation in life expectancy at
birth in England and Wales is largely explained by deprivation. J Epidemiol Community
Health 2005;59:115e20.
13. Neighbourhood Renewal Unit. The English indices of deprivation 2004 (revised).
London: Ofﬁce for the Deputy Prime Minister, 2004.
14. Cancer Research UK Cancer Survival Group. Strel computer program version 1.2
for cancer survival analysis. London School of Hygiene and Tropical Medicine, 2006.
www.lshtm.ac.uk/ncdeu/cancersurvival/tools.htm (accessed 17 Dec 2010).
15. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in ﬁve continents:
a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730e56.
16. Ito Y, Ioka A, Tsukuma H, et al. Regional differences in population-based cancer
survival between six prefectures in Japan: application of relative survival models with
funnel plots. Cancer Sci 2009;100:1306e11.
17. Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat Med
2005;24:1185e202.
18. Quinn MJ, Cooper N, Rachet B, et al. Survival from cancer of the uterine cervix in
England and Wales up to 2001. Br J Cancer 2008;99(Suppl 1):59e62.
19. Kitchener HC. Clinical commentarydsurvival from cancer of the ovary in England
and Wales up to 2001. Br J Cancer 2008;99(Suppl 1):73e4.
20. Cervical Screening Programme, England: 1997e98. National Health Service, 1999.
http://www.cancerscreening.nhs.uk/cervical/cervical-statistics-bulletin-1997-98.pdf
(accessed 17 Dec 2010).
21. NHS Cervical Screening Programme. Cervical Screening Programme Review, 1999.
http://www.cancerscreening.nhs.uk/cervical/publications/1999cervical.pdf
(accessed 17 Dec 2010).
22. Stockton D, Cooper P, Lonsdale RN. Changing incidence of invasive adenocarcinoma
of the uterine cervix in East Anglia. J Med Screen 1997;4:40e3.
23. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma
relative to squamous cell carcinoma of the uterine cervix in the United Statesda
24-year population-based study. Gynecol Oncol 2000;78:97e105.
24. Sherman ME, Wang SS, Carreon J, et al. Mortality trends for cervical squamous
and adenocarcinoma in the United States. Relation to incidence and survival. Cancer
2005;103:1258e64.
25. Vinh-Hung V, Bourgain C, Vlastos G, et al. Prognostic value of histopathology and
trends in cervical cancer: a SEER population study. BMC Cancer 2007;7:164.
26. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell
carcinoma and adenocarcinoma of cervix e worldwide. Asian Pac J Cancer Prev
2009;10:645e50.
27. Mullee M, De Stavola BL, Romanengo M, et al. Geographical variation in breast
cancer survival rates for women diagnosed in England between 1992 and 1994. Br J
Cancer 2004;90:2153e6.
28. Yuen J, Haybittle J, Machin D. Geographical variation in the standardised years of
potential life lost ration (SYPLR) in women dying from malignancies of the breast in
England and Wales. Br J Cancer 1997;75:1069e74.
29. Rachet B, Ellis L, Maringe C, et al. Socioeconomic inequalities in cancer survival in
England after the NHS Cancer Plan. Br J Cancer 2010;103:446e53.
30. National Audit Ofﬁce. Tackling cancer in England: saving more lives. HC 364
Session 2003e2004, 1-64. 19-3-2004. London: The Stationery Ofﬁce, 2004.
31. Department of Health. Manual for Cancer Services. London: Department of Health,
2004.
32. National Cancer Action Team. National Cancer Peer Review Programme
2004e2007 National Report: an overview of the ﬁndings from the second round of
peer reviews of cancer services in England. London: Department of Health, 2010.
33. Blanks RG, Moss SM, McGahan CE, et al. Effect of NHS Breast Screening
Programme on mortality from breast cancer in England and Wales, 1990e8:
comparison of observed with predicted mortality. BMJ 2000;321:665e9.
34. Breast Screening Programme, England, 2005e06. NHS Information Centre, 2007.
http://www.cancerscreening.nhs.uk/breastscreen/breast-statistics-bulletin-2005-06.
pdf (accessed 17 Dec 2010).
35. Cheung S, Greenway N, Lagord C, et al. All Breast Cancer Report: a UK analysis of
all symptomatic and screen-detected breast cancers diagnosed in 2006: NHS Breast
Screening Programme, 2009. http://www.wmpho.org.uk/wmciu/documents/All%
20Breast%20Cancer%20Report%20pp.pdf (accessed 17 Dec 2010).
36. Alexander F, Weller D. Evaluation of the UK Colorectal Cancer Screening Pilot. The
UK CRC Screening Pilot Evaluation Team, 2003. http://www.cancerscreening.nhs.uk/
bowel/ﬁnalreport.pdf (accessed 17 Dec 2010).
37. Department of Health. Cancer reform strategy. London, Department of Health, 2007:1e17.
38. UK Association of Cancer Registries (UKACR). Data quality. http://www.ukacr.
org/content/data-quality. (accessed 5 Nov 2010).
39. NHS Clinical and Health Outcomes Knowledge Base: NCHOD, 2010. http://www.
nchod.nhs.uk (accessed 10 Aug 2010).
PAGE fraction trail=9
1052 J Epidemiol Community Health 2011;65:1044e1052. doi:10.1136/jech.2010.126656
Cancer